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Background: The metalloproteinase family of a disintegrin and metalloproteinase with thrombospondin motifs
(ADAMTS) degrades extracellular matrix. However, the relevance of the ADAMTS family to cardiovascular diseases
remains largely unknown. The study aimed to examine plasma ADAMTS-7 levels in patients with acute myocardial
infarction (AMI) and the relationship between plasma ADAMTS-7 levels and heart function.
Methods: This was a prospective study performed in 84 patients with ST-elevation myocardial infarction (STEMI),
70 patients with non-STEMI (NSTEMI), and 38 controls. Enzyme-linked immunosorbent assay (ELISA) was used to measure
plasma ADAMTS-7 levels. Cardiac structure and function were assessed using two-dimensional transthoracic
echocardiography. Patients were stratified according to left ventricular ejection fraction (LVEF) ≤35% or >35%.
Results: Plasma ADAMTS-7 levels were higher in patients with LVEF ≤35% compared with those with LVEF >35%
(6.73 ± 2.47 vs. 3.22 ± 2.05 ng/ml, P < 0.05). Plasma ADAMTS-7 levels were positively correlated with brain natriuretic
peptide (BNP), left ventricular mass index (LVMI), left ventricular end-diastolic diameter (LVEDD), and left ventricular
end-systolic diameter (LVESD) and negatively correlated with the 6-min walk test (P < 0.05). According to the receiver
operating characteristic (ROC) curve, using a cutoff value of plasma ADAMTS-7 of 5.69 ng/ml was associated with a
specificity of 61.0% and a sensitivity of 87.6% for the diagnosis of heart failure after AMI. Logistic regression analysis
indicated that the association between ADAMTS-7 and heart failure after AMI was independent from traditional
cardiovascular risk factors and other biomarkers (odds ratio = 1.236, 95% confidence interval: 1.023 to 1.378, P = 0.021).
Conclusions: Elevated ADAMTS-7 level may be involved in ventricular remodeling after AMI.
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An increasing number of patients are suffering from
heart failure after acute myocardial infarction (AMI),
which is associated with high morbidity and mortality
[1,2]. Ventricular remodeling plays an essential role in
the development of heart failure, and the extracellular
matrix (ECM) plays a major role in the maintenance of
ventricular shape, size, and function [3]. After AMI, very
early degradation of ECM causes progressive dilation
and thinning in the infarction zone, contributing to* Correspondence: victorzheng@sina.com
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cluding left ventricular (LV) rupture, dilation, and dys-
function [4]. In addition, subsequent ECM disruption in
the non-infarction zone leads to progressive global LV
dilation over weeks [4].
ECM degradation requires the activation of extracellu-
lar proteases, which in turn facilitates ventricular remod-
eling [5]. Matrix metalloproteinases (MMP) play an
important role in matrix degradation and ventricular re-
modeling [6,7]. MMP activation and consequent fibrillar
collagen breakdown are responsible for adverse ventricu-
lar remodeling [8]. However, broad-spectrum MMP
inhibitors led to severe side effects in clinical trials, indi-
cating that more comprehensive knowledge about pro-
teinases is needed [9].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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family of a disintegrin and metalloproteinase with
thrombospondin motifs (ADAMTS) also degrade ECM.
However, the relevance of the ADAMTS family to
cardiovascular disease remains largely unknown [10].
ADAMTS-7 degrades cartilage oligomeric matrix pro-
teins (COMP) found in the heart [11] and has been
involved in inflammatory arthritis and bone growth
[10,12]. Recently, Wang et al. [13] reported that
ADAMTS-7 was a novel proteolytic culprit in vascular
remodeling by mediating vascular smooth muscle cell
migration and neointima formation in balloon-injured
rat arteries [14], as well as in neointimal thickening after
cardiac injury [15]. Du et al. [16] reported that upregula-
tion of ADAMTS-7 by miR-29 repression mediated
vascular smooth muscle calcification. ADAMTS-7 is in-
volved in the proliferative response to vascular injury in
a way that is similar to the progressive phase of athero-
sclerosis [17].
Therefore, we hypothesized that ADAMTS-7 partici-
pates in ventricular remodeling mediated, at least in
part, by ADAMTS-7-dependent ECM degradation. In
this pilot study, we selected patients with AMI (both
ST-elevation myocardial infarction (STEMI) and non-
STEMI (NSTEMI)) to detect plasma ADAMTS-7 levels




Patients with AMI hospitalized between December 2012
and December 2013 at the cardiology department of the
China-Japan Friendship Hospital were recruited, includ-
ing 84 patients with STEMI and 70 patients with
NSTEMI. Thirty-eight controls were also recruited from
patients who underwent angiography and who subse-
quently showed no evidence of AMI. The diagnostic cri-
teria for STEMI and NSTEMI were based on the 2013
ACCF/AHA guidelines for the management of STEMI
[18], and the 2011 ESC guidelines for the manage-
ment of acute coronary syndrome without ST-segment
elevation [19].
For patients with STEMI or NSTEMI, inclusion cri-
teria were as follows: 1) positive for troponin I; 2) history
of chest pain lasting ≥20 min, no response to nitrogly-
cerine or ECG changes (STEMI: ST-segment elevation
measured at J-point in two continuous leads or with
new onset of left bundle branch block; NSTEMI: ST-
segment shifts and T-wave changes); 3) patient pre-
sented at the hospital within 24 h of symptoms onset;
4) patient consented to the study and blood was sampled
for ADAMTS-7 measurement before any intervention;
and 5) signed the consent form. For controls, inclusion
criteria were as follows: 1) complaints of ischemic pains;2) angiography showed vascular stenosis <50%; 3) patient
consented to the study, and blood was sampled for
ADAMTS-7 measurement before any intervention; and
4) signed the consent form. For all subjects, exclusion cri-
teria were as follows: 1) severe hepatic or renal insuffi-
ciency; 2) rheumatologic disorders; 3) malignancy; or
4) active infection.
The study protocol was approved by the research ethics
committee of the China-Japan Friendship Hospital and all
patients provided a written informed consent.
Data collection
Gender, age, body mass index (BMI), medical history,
and results of laboratory examinations were collected
from the hospital computer system.
Sample collection
Six-milliliter samples of whole blood were collected into
EDTA anticoagulant tubes and were stored at 4°C. Sam-
ples were centrifuged for 15 min at 1,000 × g at 4°C
within 30 min of collection. Samples were stored at −80°C
until analysis.
Plasma ADAMTS-7 levels and biochemical assays
Plasma ADAMTS-7 levels were measured using an
enzyme-linked immunosorbent assay (ELISA) for hu-
man ADAMTS-7 (Human ADAMTS-7 ELISA Kit;
MyBioSource Inc., San Diego, CA, USA). Optical density
was measured at 450 nm. The lowest detectable limit of
ADAMTS-7 concentration was 1.529 ng/mL, according to
the manufacturer’s instructions, and the coefficient of vari-
ation was <10%. Brain natriuretic peptide (BNP), serum
lipids, high-sensitivity C-reactive protein (hs-CRP), fasting
blood glucose, and serum creatinine were measured using
standard clinical methods at the China-Japan Friendship
Hospital using a Hitachi 7600 series automatic analyzer
(Hitachi, Tokyo, Japan).
Echocardiography
Cardiac structure and function were assessed using two-
dimensional transthoracic echocardiography performed
and interpreted by cardiologists specialized in echocardi-
ography and who were blind to the patient’s clinical
status. Echocardiography was performed using a Vivid
E9 Echopac system with a high-definition M5S probe
(GE Healthcare, Waukesha, WI, USA). Gain settings and
pulse repetition frequency were adjusted to optimize
color saturation and to avoid aliasing. LV ejection frac-
tion (LVEF) was calculated using the biplane Simpson
method. LV end diastolic/systolic diameter (LVEDD/
LVESD) and interventricular septum thickness (IVST)
were measured and recorded [20]. The LV mass (LVM)
was derived using the following formula: LVM (g) = 0.8 ×
(1.04 × (IVST + LVEDD+ LVPWT)3 − LVEDD3) + 0.6 [21],
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thickness. LVM was subsequently adjusted for body
surface area (BSA) to obtain the LVM index (LVMI)
value: LVMI (g/m2) = LVM/BSA.
Patients with STEMI or NSTEMI were divided into
two groups according to a LVEF ≤35% or >35%.
Six-min walk test
The 6-min walk test was conducted in an enclosed 30-
m-long corridor. The patients were instructed to walk
from end to end, covering as much ground as they could
during the 6 min test. The supervisor sat in a chair at one
end of the course and delivered a predetermined set of en-
couraging phrases such as ‘You are doing well’ or ‘Keep up
the good work.’ The total distance was recorded.
Statistical analysis
SPSS 19.0 (IBM, Armonk, NY, USA) and Prism 5.0
(GraphPad Software Inc., San Diego, CA, USA) were
used for data analysis. Descriptive data are presented asTable 1 Characteristics of the patients
Characteristics LVEF ≤35% (n = 42)
Age, years 66.5 ± 12.4
Gender, male/female 28/14 (66.7/33.3%)
BMI (kg/m2) 24.4 ± 3.0
History of smoking, n (%) 12 (28.6)
Serum creatinine >140 μmol/L, n (%) 13 (30.95)a
History of hypertension, n (%) 28 (66.7)
History of diabetes, n (%) 19 (45.2)
Glucose (mmol/L) 8.17 ± 3.86
Total cholesterol (mmol/L) 4.64 ± 0.85
Triglycerides (mmol/L) 1.59 ± 1.21
HDL-cholesterol (mmol/L) 1.07 ± 0.33
LDL-cholesterol (mmol/L) 2.83 ± 0.84
hsCRP (mg/L) 12.32 ± 53.46
Type of AMI, n (%)
STEMI 33 (78.6)
NSTEMI 9 (21.4)
BNP 1,670.71 ± 1,074.44a
LVEF 28.43 ± 4.79a
LVMI 90.51 ± 14.39a
LVEDD 61.95 ± 4.80a
LVESD 38.05 ± 5.73a
Six-min walk test 171.07 ± 70.32a
Plasma ADAMTS-7 levels 6.73 ± 2.47a
aMean P < 0.05 compared between the LVEF ≤35 group and LVEF >35% group; bme
metalloproteinase with thrombospondin motifs; AMI, acute myocardial infarction; B
lipoprotein; hsCRP, high-sensitivity C-reactive protein; STEMI, ST-elevation myocardi
natriuretic peptide; LVEF, left ventricular ejection fraction; LVMI, left ventricular mas
end-systolic diameter.means ± standard deviation (SD) for normally distributed
variables or as medians (interquartile range) for non-
normally distributed variables and as frequencies for cat-
egorical variables. Comparisons were performed using
independent t-tests (normally distributed), Mann–Whitney
U-tests (non-normally distributed), or chi-squared tests
(categorical data). Receiver operating characteristic (ROC)
curve was used to determine specificity and sensitivity for
predicting heart failure after AMI. Linear associations were
assessed using the Kendall’s tau-b analysis. Binary logistic
regression was used to identify the predictive impacts of
plasma ADAMTS-7 on heart failure. The odd ratios (OR)
and the corresponding 95% confidence intervals (95% CI)




Age and frequency of hypertension, diabetes, and male
gender were higher in patients with AMI compared withLVEF >35% (n = 112) Controls (n = 38) P valueb
68.7 ± 10.4 56.6 ± 11.5 <0.05
71/41 (63.4/36.6%) 21/17 (55.6%/44.7%) <0.05
24.7 ± 3.8 26.1 ± 4.1 0.23
30 (26.5) 11 (28.9) 0.42
6 (5.36)a 0 (0.00) <0.05
73 (65.2) 16 (42.1) <0.05
54 (48.2) 9 (23.7) <0.05
8.42 ± 3.56 5.64 ± 1.21 0.23
4.36 ± 1.17 4.66 ± 0.89 0.90
1.38 ± 0.72 1.88 ± 1.34 0.08
1.12 ± 0.29 1.06 ± 0.32 0.06
2.72 ± 0.94 2.76 ± 0.64 0.97




433.72 ± 285.67a 60.69 ± 36.98 <0.05
47.31 ± 7.69a 57.42 ± 6.28 <0.05
70.43 ± 12.04a 82.67 ± 20.05 <0.05
49.45 ± 4.72a 50.23 ± 5.98 <0.05
31.37 ± 4.08a 30.37 ± 4.15 <0.05
465.13 ± 189.00a <0.05
3.22 ± 2.05a 1.63 ± 1.58 <0.05
an comparison between the three groups. ADAMTS, a disintegrin and
MI, body mass index; HDL, high-density lipoprotein; LDL, low-density
al infarction; NSTEMI, non-ST-elevation myocardial infarction; BNP, brain
s index; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular
Figure 1 ROC curve analysis of plasma ADAMTS-7 levels for
the prediction of heart failure after AMI. ROC, receiver
operating characteristic.
Wu et al. European Journal of Medical Research  (2015) 20:27 Page 4 of 6controls (P < 0.05). The proportion of patients with
serum creatinine >140 μmol/l was significantly higher in
patients with AMI. There were no differences in BMI,
blood glucose, and blood lipids between groups (Table 1).
Levels of high-sensitivity C-reactive protein (hsCRP)
were elevated in patients with AMI compared with con-
trols (P < 0.05).
Plasma ADAMTS-7 in patients with AMI and LVEF ≤35%
or LVEF >35%
Patients with AMI were divided according to LVEF ≤35%
or >35%. Plasma levels of ADAMTS-7 were higher in
patients with LVEF ≤35% compared with those with
LVEF >35% (6.73 ± 2.47 vs. 3.22 ± 2.05 ng/ml, P < 0.05).
Association between ADAMTS-7 levels and heart failure
The median ADAMTS-7 level among the 154 patients
with AMI (84 STEMI patients and 70 NSTEMI patients)
was 4.48 ng/ml (range: 0.34 to 14.26 ng/ml). Kendall’s
tau-b analysis showed that plasma ADAMTS-7 levels were
positively correlated with BNP (r = 0.732, P = 0.005), LVMI
(r = 0.714, P = 0.02), LVEDD (r = 0.693, P = 0.04), and
LVESD (r = 0.647, P = 0.03) and negatively correlated with
the 6-min walk test (r = −0.653, P = 0.02) and LVEF
(r = −0.624, P = 0.04) (Table 2).
According to the ROC curve, a cutoff value of plasma
ADAMTS-7 of 5.68 ng/ml resulted in a specificity of
61.0% and a sensitivity of 87.6% for the diagnosis of
heart failure after AMI (Figure 1).
To control for potential confounders, a multivariate
analysis was performed. Age, gender, BMI, hypertension,
hyperlipidemia, diabetes, blood glucose, total cholesterol,
triglycerides, high-density lipoprotein (HDL)-cholesterol,
low-density lipoprotein (LDL)-cholesterol, and hsCRP
were set as independent variables, and heart failure
was set as the dependent variable. Results indicated
that elevated plasma ADAMTS-7 levels were inde-
pendently associated with heart failure after AMI
(OR = 1.236, 95% CI: 1.023 to 1.378, P = 0.021) as well asTable 2 Correlation between ADAMTS-7 levels and clinical
parameters in patients with AMI





Six-min walk test −0.653 0.024
LVEF −0.624 0.041
ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs;
AMI, acute myocardial infarction; BNP, brain natriuretic peptide; LVEF, left
ventricular ejection fraction; LVMI, left ventricular mass index; LVEDD, left
ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter.age (OR = 1.158, 95% CI: 1.013 to 1.438, P = 0.035) and
hsCRP (OR = 1.285, 95% CI: 1.002 to 1.411, P = 0.016)
(Table 3).
Discussion
The aim of the present study was to examine plasma
ADAMTS-7 levels in patients with AMI and the rela-
tionship between plasma ADAMTS-7 levels and heart
function. Results showed that plasma ADAMTS-7 levels
were higher in patients with LVEF ≤35% compared with
those who had a LVEF >35%. Plasma ADAMTS-7 levels
were positively correlated with BNP, LVMI, LVEDD, and
LVESD and negatively correlated with the 6-min walk
test, which is consistent with the role of MMP in theTable 3 Multivariate analysis of factors associated with
heart failure after AMI
Variables P value Exp (B) 95% CI for Exp (B)
Age 0.035 1.158 1.013 to 1.438
Gender 0.093 1.213 0.872 to 1.365
BMI 0.523 1.233 0.721 to 1.259
Hypertension history 0.269 1.000 0.963 to 1.101
Hyperlipidemia history 0.436 0.983 0.925 to 1.028
Diabetes history 0.377 0.797 0.740 to 1.029
hsCRP 0.016 1.285 1.002 to 1.411
Plasma ADAMTS-7 0.022 1.242 1.015 to 1.378
95% CI, 95% confidence interval; ADAMTS, a disintegrin and metalloproteinase
with thrombospondin motifs; AMI, acute myocardial infarction; BMI, body mass
index; hsCRP, high-sensitivity C-reactive protein.
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to the ROC curve, using a cut-off value of plasma
ADAMTS-7 of 5.69 ng/ml was associated with a specifi-
city of 61.0% and a sensitivity of 87.6% for the diagnosis
of heart failure after AMI. Logistic regression analysis
indicated that the association between ADAMTS-7 and
heart failure after AMI was independent of traditional
cardiovascular risk factors and other biomarkers.
The early induction of the enzymatic activity of ECM-
degrading proteases precedes ventricular remodeling.
From the therapeutic standpoint, inhibition of such pro-
teases would be beneficial for the treatment of patients
with heart failure. Given the disappointing side effects of
broad-spectrum MMP inhibitors, more comprehensive
knowledge about proteinases is needed [9]. Thus, unrav-
eling the role of individual proteases in cardiovascular
disease is of particular importance. To the best of our
knowledge, the present study is the first to show an as-
sociation between plasma ADAMTS-7 levels and LV
function after AMI. Indeed, low LVEF after AMI is indi-
cative of more extensive cardiac damage and is associ-
ated with a bad prognosis [23]. However, the exact
implication of ADAMTS-7 in ventricular remodeling
still needs to be exactly determined.
Unlike other metalloproteinases, ADAMTS demon-
strates a narrow substrate specificity due to the various
exosites located in the C-terminal regions of the en-
zymes, which influence protein recognition and matrix
location [24], suggesting that ADAMTS could poten-
tially be safe pharmaceutical targets [13]. ADAMTS-7
expression was detected as a 5-kb transcript in adult hu-
man samples, with the heart, pancreas, kidney, skeletal
muscle, and liver having the highest levels of expression
[13]. Previous studies demonstrated that ADAMTS-7 fa-
cilitates vascular muscle cell migration and intimal
thickening after vascular injury and plays an important
role in atherosclerosis and restenosis by degrading
COMP [13-16]. Huang et al. [25] reported the presence
of COMP in cardiomyocytes, where it plays an essential
role during the initiation and progression of dilated car-
diomyopathy. Therefore, it may be hypothesized that
ADAMTS-7 affects the ventricular remodeling process
by degrading COMP in patients with AMI. However, it
is possible that ADAMTS-7 degrades other substrates.
Nevertheless, a study showed an association between the
ADAMTS-7 locus and angiographic coronary artery dis-
ease [15]. Further studies are necessary to assess the
mechanisms of ADAMTS-7 in ventricular remodeling
and heart diseases. Other members of the ADAMTS
family also warrant investigation in AMI [26].
The present study is not without limitations. This was
a single-center study with a relatively small sample size.
For now, the cutoff value is purely suggestive since there
is no established reference available from large clinicaltrials. Finally, the present study was not designed to
provide any mechanistic insights into the roles of
ADAMTS-7 in patients with heart failure after AMI.
Larger multi-center trials are necessary to determine ad-
equately the role of ADAMTS-7 in heart failure after
AMI.
Conclusions
In conclusion, elevated ADAMTS-7 levels may be
involved in ventricular remodeling after AMI. High
ADAMTS-7 levels were independently associated with
poor prognosis in patients with AMI.
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